INDIA MARKET LENS

Ajanta Pharma Limited (AJANTPHARM): research summary

Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Ajanta Pharma Limited, explained in plain English.

  • Ajanta Pharma Limited is tracked in the Pharma & Healthcare sector of the NSE universe covered here.
  • AJANTPHARM closed at ₹3,317.70 on 20 November 2026.
  • Over the past year the shares are up 32.1%, trading between ₹2,465.00 and ₹3,796.00.
  • Reported fundamentals show return on equity of 27.53%, a net margin of 20.31%, debt to equity of 3.17.
  • Our Pulse grade checklist scores it A (81/100) across momentum, growth, profitability and safety on fixed thresholds.
  • Annualised volatility over the past year is 25.88% with a maximum drawdown of -13.16% and a beta of 0.43 against NIFTY 50.

Other Pharma & Healthcare companies: Abbott India, Acutaas Chemicals, Alkem Laboratories, Anthem Biosciences, Apollo Hospitals Enterprise, Aster DM Quality Care, Aurobindo Pharma, Biocon

Last traded values from 20 Nov 2026. Closed — weekend.

Ajanta Pharmaceuticals (AJANTPHARM)

₹3,283.9

▲ 13.6 (+0.42%)

Price & volume

AJANTPHARM price chart, 1Y range. 252 points from 2025-11-20 to 2026-11-20. Opens at 2,510.7, closes at 3,283.9, ranging between 2,485.7 and 3,718.2.2,5003,0003,500Nov-25Jan-26Mar-26May-26Jun-26Aug-26Sep-26Nov-26volume

Hover for exact price & volume · green/red volume bars show up vs down days

Weak momentum · 1/5
✕ Above 50-day avg✓ Above 200-day avgRSI 43.1 · healthyMACD negativeBollinger %B 27ADX 9.7 · weak trend

1M

-0.45%

3M

-10.24%

6M

+2.98%

1Y

+30.80%

Where it sits in its 52-week range

65%
₹2,485.7₹3,718.2

Below 52-week high

11.7%

32.1% above the low

Momentum read

Weak

1/5 checks passed

52-wk high

₹3,718.2

52-wk low

₹2,485.7

Market cap

—

P/E (trailing)

—

Dividend yield

—

ROE

—

Profit margin

—

Revenue growth

—

Price / Book

—

Debt / Equity

—

EPS (TTM)

—

Book value

—

Beta

0.43

Pulse grade: F, 22 out of 100

Momentum

F
  • ✕Trading above 50-day average
  • ✓Trading above 200-day average
  • ✕RSI in healthy 45-70 zone
  • ✕Positive 3-month return

Growth

D
  • ✕Revenue growth above 12%
  • ✕Revenue growing above 5%
  • ✓Quarterly profits trending up

Profitability

F
  • ✕Return on equity above 18%
  • ✕Return on equity above 12%
  • ✕Profit margin above 12%

Safety

F
  • ✕Debt below 50
  • ✕Debt not extreme for the sector
  • ✓Less volatile than the market (beta < 1.2)
  • ✕Pays a dividend

Quarterly revenue vs net profit

Revenue Net profit₹ crore, by quarter

Sep 2026: revenue ₹1,794 crore · net profit ₹388 crore · margin 21.6%

1,7940Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026

Business quality

Intrinsic value

Building the model…

Analyst coverage

Who owns this company

Events, dividends & splits

Market position

Pharma & Healthcare sector

PeerPrice ₹Day changeFrom 52-wk high
SUNPHARMA1,887.2-0.67%-5.69%
DRREDDY1,396.6-0.11%-0.31%
CIPLA1,411.2-0.51%-7.84%
DIVISLAB11,083-0.85%-4.17%
APOLLOHOSP9,131.5+4.50%+0.69%
LUPIN1,991.8-0.35%-20.80%

AJANTPHARM headlines

No AJANTPHARM stories right now.

AJANTPHARM filings & announcements

Reading the exchange…

AJANTPHARM, historical timeline

The timeline will be ready shortly

The rest of the page is unaffected.

Risk & return, last 12 months

Volatility (ann.)

25.85%

Sharpe ratio

0.93

Sortino ratio

1.46

Max drawdown

-13.16%

Daily VaR (95%)

-2.49%

CAGR (1Y)

30.94%

Return skew

0.6

Sharpe/Sortino use a 7% risk-free rate. VaR-95 = the daily loss exceeded only 5% of days last year.

Risk profile over time

Quant tearsheet

Monthly returns, how deep the falls ran, and how tightly it tracks NIFTY.